Selected data models

You must log in to select data models for download or further analysis.

87 Search results.
Relevance Rating New first Old first

Pancreatic Cancer NCT00058149 Quality of Life - Brief Pain Inventory - 2031356v3.0 - Brief Pain Inventory

- 1/9/15 - 1 form, 2 itemgroups, 23 items, 1 language
Itemgroups: Header, CCRR MODULE
Brief Pain Inventory A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=AE65F8E1-704E-30A0-E034-0003BA12F5E7

Pancreatic Cancer NCT00088894 - EQ-5D FORM Pancreatic Cancer CALGB NCT00088894

- 7/2/17 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Header, EQ-5D
CALGB: EQ-5D FORM Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D602C703-1CB1-3D8F-E034-0003BA12F5E7

Pancreatic Cancer NCT00058149 Follow-Up - Hematology/Chemistry Form - 2048132v3.0 - Hematology/Chemistry Form

- 1/21/15 - 1 form, 2 itemgroups, 31 items, 1 language
Itemgroups: Header, Hematology and Chemistry
Hematology/Chemistry Form A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A65D4877-9B57-427A-E034-0003BA0B1A09

On-Study - Resectable Pancreatic Cancer - On-Study Form - 2020205v2.31 - Resectable Pancreatic Cancer - On-Study Form

- 1/8/15 - 1 form, 3 itemgroups, 25 items, 1 language
Itemgroups: CRF Header, PANCREATIC: FORM ADMINISTRATION, PANCREATIC: DISEASE DESCRIPTION
Resectable Pancreatic Cancer - On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=99CD59C5-A9AA-3FA4-E034-080020C9C0E0

On-Study - Unresectable Pancreatic Cancer - On-Study Form - 2020206v2.31 - Unresectable Pancreatic Cancer - On-Study Form

- 1/8/15 - 1 form, 3 itemgroups, 25 items, 1 language
Itemgroups: CRF Header, PANCREATIC: FORM ADMINISTRATION, PANCREATIC: DISEASE DESCRIPTION
Unresectable Pancreatic Cancer - On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=99CD59C5-A9AC-3FA4-E034-080020C9C0E0

Baseline Laboratory test form pancreatic cancer SWOG S0205 NCT00075686

- 9/24/15 - 1 form, 2 itemgroups, 35 items, 1 language
Itemgroups: Header, BASELINE LAB TEST RESULTS
BASELINE LABORATORY TEST RESULT FORM - 2307541v3.0 SOUTHWEST ONCOLOGY GROUP S0205 BASELINE LABORATORY TEST RESULT FORM S0205 Gemcitabine With or Without Cetuximab as First-Line Therapy in Treating Patients With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=F2FD3D46-E071-663C-E034-0003BA3F9857

Pancreatic Cancer NCT00733746 Registration - ACOSOG-Z5041 Registration Worksheet - 2921129v1.0 - ACOSOG-Z5041 Registration Worksheet

- 9/20/21 - 1 form, 4 itemgroups, 34 items, 1 language
Itemgroups: Header Module, Eligibility Criteria, Diagnosis and Therapy, Specimen Banking Consent
ACOSOG-Z5041 Registration Worksheet Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6F3D4C5B-FB42-7755-E040-BB89AD432E97

On-Study - Curative Treatment for Head and Neck Cancer - On-Study Form - 2268312v3.0 - Curative Treatment for Head and Neck Cancer - On-Study Form

- 9/20/21 - 1 form, 5 itemgroups, 48 items, 1 language
Itemgroups: CRF Header, Head & Neck: Form Administration, Head & Neck: Patient Assessment, Head & Neck: Disease Description, Head & Neck: Prior Health History - Curative
Curative Treatment for Head and Neck Cancer - On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D4976276-569A-5CEB-E034-0003BA12F5E7

Pancreatic Cancer NCT00733746 Registration - Z5041 - OPEN Enrollment Form - 3013792v1.0 - Z5041 - OPEN Enrollment Form

- 9/17/21 - 1 form, 3 itemgroups, 44 items, 1 language
Itemgroups: Demography Section, General Information, Eligibility Checklist
Z5041 - OPEN Enrollment Form Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=7FFA1514-8347-A58F-E040-BB89AD4376E5

CALGB: C-1001 NEW PRIMARY CANCER FORM [80303] NCT00088894

- 6/21/15 - 1 form, 4 itemgroups, 15 items, 1 language
Itemgroups: Header, Patient demographics, NEW PRIMARY CANCER ASSESSMENT, Comments
CALGB: C-1001 NEW PRIMARY CANCER FORM [80303] NCT00088894 Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D5FEE4C9-F395-6F2C-E034-0003BA12F5E7

Pancreatic Cancer NCT00075686 Toxicity - S0205 Toxicity and Dosage Form - 2035853v3.0 - S0205 Toxicity and Dosage Form

- 1/9/15 - 1 form, 5 itemgroups, 30 items, 1 language
Itemgroups: Header, DISEASE STATUS, TREATMENT, Comments, TOXICITY
S0205 Toxicity and Dosage Form S0205 Gemcitabine With or Without Cetuximab as First-Line Therapy in Treating Patients With Locally Advanced Unresectable or Metastatic Adenocarcinoma of the Pancreas Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A1204548-9EF3-3AA5-E034-080020C9C0E0

Pancreatic Cancer NCT00058149 Response - E6201 Cover Page for Supplemental Form - 2075318v3.0 - E6201 Cover Page for Supplemental Form

- 1/9/15 - 1 form, 4 itemgroups, 12 items, 1 language
Itemgroups: Header, On Treatment, Off Treatment, CCRR MODULE
E6201 Cover Page for Supplemental Form A Phase III, Randomized Study of Gemcitabine (Fixed-Dose Rate Infusion) and Oxaliplatin (NSC 266046) Versus Gemcitabine (Fixed-Dose Rate Infusion) Versus Gemcitabine (30-Minute Infusion) in Pancreatic Carcinoma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=B1B0ADEE-BA19-4B20-E034-0003BA12F5E7

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial